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http:WHAT THIS PAPER ADDS
The aortic augmentation index is a surrogate marker for arterial stiffness and cardiovascular mortality. This study
shows for the ﬁrst time that an endovascular revascularisation in claudicants is associated with an improvement
of this marker, indicating beneﬁcial systemic vascular effects beyond the improvement in perfusion of the
treated leg.Objectives: The aortic augmentation index (AIx), a marker of arterial stiffness, and peripheral arterial disease
(PAD) are associated with an increased cardiovascular risk. In claudicants, the effect of balloon angioplasty
(percutaneous transluminal angioplasty, PTA) on AIx has not been determined so far.
Methods: Measurements of the ankleebrachial pressure index (ABI) and AIx were performed before and 3
months after PTA and compared to age- and sex-matched PAD patients under best medical treatment.
Results: The data of 61 patients (44% female, mean age 68 years) who underwent lower-limb PTA was compared
to 48 conservatively treated patients (38% female, mean age 68 years). ABI signiﬁcantly improved after PTA from
0.73  0.02 to 0.85  0.03 (p ¼ 0.001), but remained unchanged in the control group (0.85  0.23 and
0.80  0.21; p ¼ 0.16). Revascularisation was associated with a signiﬁcant reduction of AIx from 31.5  1.1% to
28.8  1.1% after 3 months (p ¼ 0.01). In the conservatively treated group, AIx did not change during follow-up
(29.9  1.1% to 29.9  1.1%; p ¼ 0.83).
Conclusion: Lower-limb revascularisation in PAD Rutherford stage IIeIII is associated with an improvement of
markers for arterial stiffness.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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elderly population and is associated with an increased risk for
cardiovascular events such as myocardial infarction and
stroke.1e6 The severity of PAD is a marker for the atheroscle-
rotic burden in other vascular beds, and a correlation between
the ankleebrachial arterial pressure index (ABI) and mortality
has been reported.3 Patients with critical limb ischaemia have
the lowest survival rate with an annual cardiovascular
mortality rate of 25%.7 Patients with claudication or even
asymptomatic PAD have a ﬁve- to 10-fold greater risk of
myocardial infarction and stroke than a control population.1
Despite this astonishing epidemiologic data, the mecha-
nisms through which PAD is associated with this increased
risk are still not fully understood. So far, possible explana-
tions are increased markers of inﬂammation and oxidative
stress that eventually impact acute vascular events.8 Inrresponding author. Tel.: þ41 44 255 26 71; fax: þ41 44 255 45 10.
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//dx.doi.org/10.1016/j.ejvs.2013.01.026addition, reduced ambulatory activity due to claudication is
closely associated with cardiovascular morbidity and
mortality in patients with atherosclerotic disease.9e11
Furthermore, altered arterial-wall properties, such as arte-
rial stiffness, might be another mechanism due to which
patients with PAD had an increased cardiovascular risk. The
augmentation index (AIx), derived from the aortic-pressure
waveform acquired by applanation tonometry, is a surro-
gate marker of arterial stiffness and correlates with
cardiovascular mortality.12e14
Several authors have already demonstrated an associa-
tion between ABI and Alx.15e17
So far, the effect of lower-limb revascularisation in patients
with PAD on AIx has not been studied. Since endovascular
procedures improve ABI, we hypothesise that lower-limb
revascularisation may improve AIx in claudicants.METHODS
Study design and patients
The study was conducted at a tertiary referral centre as
a prospective, non-randomised, single-centre, controlled
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all patients gave written informed consent.
Patients with stable PAD Rutherford stage IIeIII of at least
for 6 months without improvement during non-supervised
walking exercise and substantial limitation in their walking
capacity affecting their quality of life underwent endovas-
cular revascularisation (group A). Patients with Rutherford
stage IeII who did not feel substantially limited in their daily
life received best medical treatment and without revascu-
larisation (group B). Exclusion criteria were critical limb
ischaemia (Rutherford IVeVI), cardiac arrhythmia, chronic
inﬂammatory vascular disorders or failed revascularisation
deﬁned as more than 50% residual stenosis conﬁrmed
angiographically or by duplex ultrasound after the procedure.
Patients were graded in Rutherford stages by medical history.
The following data were collected at baseline and after 3
months: medical history, cardiovascular risk factors, co-
morbidities, medication, systolic and diastolic blood pres-
sure, body mass index, ABI and radial artery pulse-wave
analysis. At the follow-up, a duplex scan was performed if
indicated based on clinical and vascular examinations.
Ankleebrachial arterial pressure index and radial artery
pulse-wave analysis
The ankleebrachial arterial pressure index (ABI) was
assessed with the patient in the supine position. Systolic
ankle blood pressure of the posterior and anterior tibial
artery and of the peroneal artery in both legs was obtained
with a hand-held 6-MHz Doppler probe (Kranzbühler, Logi-
dop 2, Pilger Medical Electronics, Switzerland). The ABI was
calculated for each leg as the ratio of the highest systolic
blood pressure in the ankle divided by the highest brachial
systolic blood pressure. The ABI of the limiting leg was taken
as the study parameter.
Alx was derived via a waveform measured at the radial
artery using the SphygmoCor system (AtCor Medical; Syd-
ney, Australia) as previously described;18 this measurement
was performed by a single investigator with patients in the
supine position. The aortic-pressure waveform was derived
from the radial waveform recorded using applanation
tonometry with a high-ﬁdelity micromanometer (Millar
Instruments, Houston, TX, USA) and a previously validated
generalised transfer function.19,20 Aortic augmentation
pressure was calculated as the difference between the ﬁrst
and the second systolic peaks of the ascending aortic
waveform, and AIx was expressed as a percentage of pulse
pressure (the difference between central systolic and dia-
stolic pressure). Because AIx is inﬂuenced by heart rate, an
index normalised for a heart rate of 75 bpm was used, in
accordance with Wilkinson et al.21
Medical treatment and endovascular procedure
All patients were treated according to guidelines with
antiplatelet and/or anticoagulation, statins and antihyper-
tensive therapy if indicated.
In addition to best medical treatment, patients in the
percutaneous transluminal angioplasty (PTA) group (A) weretreated with standard balloon angioplasty in the standard
manner using a 4Fe6F sheath introduced into the femoral
common artery. Stent implantation was additionally per-
formed at the discretion of the interventionist. At the
beginning of the procedure, all patients received 5000 IU
heparin i.a. Medication remained unchanged except for
clopidogrel given over a period of 28 days in the case of
stent implantation.
Statistical analysis
Data are expressed as mean  standard error with range in
parenthesis. Data were analysed with StatView 5.0.1. soft-
ware (Adept Scientiﬁc, Acton, MA, USA), using the Manne
Whitney-U test or Fisher’s exact test for intergroup
comparison and the Wilcoxon signed-rank test for intra-
group comparison. Values of two-sided p <0.05 were
considered statistically signiﬁcant.
RESULTS
The effect of PTA on AIx and ABI was assessed in 61 patients
(group A: 44% female, mean age 68.7 years) and compared
to 48 conservatively treated patients (group B: 38% female,
mean age 68.4 years). There were no failed angioplasties.
The baseline characteristics of the patients did not differ
between the two groups (Table 1), except for ABI, which was
lower in group A (0.72  0.02) than in group B (0.84  0.23;
p ¼ 0.01), heart rate, which was higher in group A
(71.2  1.3) than in group B (65.7  1.1) and mean arterial
pressure, which was slightly lower in the intervention group
(101.3  2 vs. 106.1  1.8) as reported in Table 3.
Lesions characteristics of the revascularised patients are
summarised in Table 2.
In the PTA group, 69% (n¼ 42) had Rutherford III and 31%
(n ¼ 19) Rutherford II, whereas in the control group all
patients were Rutherford IeII. After 3 months, ABI had
improved from 0.73  0.02 to 0.85  0.03 (p ¼ 0.001) in
group A, but remained unchanged in the conservatively
treated group (0.80  0.21). At 3-months follow-up, there
was no signiﬁcant difference in ABI between the two groups
(Fig. 1).
At follow-up, no difference between the PTA and the
conservatively treated group for peripheral and central
pressure values had been found (Table 4).
In group A, revascularisation was associated with a signif-
icant reduction of AIx from 31.5 1.1% to 28.8 1.1% after
3 months (p ¼ 0.01). In contrast, there was no change in AIx
(29.9 1.1% to 29.9 1.1%; p¼ 0.83) in the conservatively
treated group between baseline and follow-up (Fig. 2).
Antihypertensive medication remained unchanged and
there were no signiﬁcant differences between the two
study groups between baseline and follow-up.
DISCUSSION
Our study shows that endovascular therapy lowers AIx,
a surrogate marker for arterial stiffness. This indicates that
peripheral revascularisation has a beneﬁcial impact on
pulse-wave function when compared to a control group
Table 3. Pressure characteristics of study population at baseline.
PTA (n ¼ 61) Control (n ¼ 48) p
Heart rate (bpm) 71.2 (1.3) 65.7 (1.1) 0.05
pSBP (mmHg) 146 (2.8) 153 (3.3) 0.07
pDBP (mmHg) 77.1 (1.4) 81.7 (1.5) 0.07
pMP (mmHg) 101.3 (2) 106.1 (1.8) 0.05
pPP (mmHg) 69 (2.1) 71.1 (2.9) 0.68
cSBP (mmHg) 130.8 (2.3) 134.8 (2.5) 0.16
cDBP (mmHg) 78.4 (1.5) 84.9 (2.3) 0.05
cPP (mmHg) 56.4 (1.9) 59.3 (2.8) 0.51
Data are mean and standard error of mean.bpm: Beats per minute,
BP: blood pressure, p: peripheral, c: central, S: systolic, D: diastolic,
MP: mean pressure, PP: pulse pressure.
Table 1. Baseline characteristics of the study population.
PTA
(n ¼ 61)
Control
(n ¼ 48)
p
BMI (kg/m2) 25.2 (0.5) 25.5 (0.6) 0.42
Female (%) 27 (44) 16 (33) 0.32
Age (years) 68.7 (1.2) 68.4 (1.7) 0.89
ABI 0.72 (0.02) 0.84 (0.23) 0.01
Cardiovascular risk factors, n (%)
Hypertension 52 (85) 38 (79) 0.45
Ever smokers 49 (80) 35 (73) 0.37
Diabetes 18 (29) 13 (27) 0.83
Dyslipidemia 42 (69) 29 (60) 0.42
Comorbidities, n (%)
Coronary artery disease 18 (29) 11 (23) 0.51
Cerebrovascular disease 19 (31) 11 (23) 0.39
Renal insufﬁciency 12 (20) 5 (10) 0.28
Medication, n (%)
Betablockers 22 (36) 24 (50) 0.17
ACE-inhibitors 20 (33) 19 (40) 0.54
ARB 17 (28) 11 (23) 0.66
CCB 19 (31) 13 (27) 0.67
Diuretics 23 (38) 20 (42) 0.69
Lipid-lowering medication 55 (90) 39 (81) 0.26
Aspirin 28 (46) 35 (73) 0.75
Clopidogrel 1 (1.5) 4 (8) n.a
Aspirin þ clopidogrel 4 (7) 3 (6) n.a
Anticoagulants 2 (3) 2 (4) n.a
Antiplatelets þ
anticoagulants
2(3) 4 (8) n.a
Data are mean and standard error of mean for quantitative
variables and number (percentages) for categorical variables. n.a:
not applicable due to sample size. ABI: ankle-brachial arterial
pressure index, ACE: angiotensin converting enzyme, ARB:
angiotensin receptor blockers, CCB: calcium channel blockers.
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a successful lower-limb revascularisation results in an
improved perfusion of the treated leg and hence in an
increase of ABI, which is not only a maker of limb perfusion
but also linked to survival.3,7 In contrast, there are few
studies that evaluated effects of peripheral interventions on
systemic markers of vascular function.22
To our knowledge, this is the ﬁrst study that examined
the effect of lower-limb revascularisation on AIx. Although
our study does not give direct mechanistic insights, thereTable 2. Lesions characteristics (n ¼ 71) of the revascularized
patients (n ¼ 61).
Lesion localisation, n (%)
Iliac 17 (24)
Femoro-popliteal 54 (76)
Lesion type, n (%)
Stenosis <5 cm length 38 (53)
Stenosis >5 cm length 17 (24)
Occlusion 16 (23)
Stenting, n (%)
Iliac 11 (16)
Femoro-popliteal 15 (21)
Stented patients 22 (36)are several potential explanations for that ﬁnding. Patients
with successful angioplasty can increase pain-free walking
distances, which, in turn, might increase physical activity.23
It has been demonstrated that cardiovascular ﬁtness is
inversely related to arterial stiffness in healthy subjects and
that lifestyle modiﬁcations such as taking up aerobic exer-
cise is an efﬁcacious therapeutic intervention to prevent
and treat arterial stiffening.24,25 Along the same lines,
Brewer et al. showed that arterial stiffness is associated
with walking distance in PAD patients by demonstrating
that a higher AIx results in shorter distance.26 We can
therefore speculate that in patients undergoing angioplasty,
the resulting reduction in AIx can be explained by improved
functional capacity. Furthermore, repeated muscle
ischaemia induces local inﬂammatory and oxidative stress
responses, with free-radical formation, neutrophil activation
and systemic vascular endothelial damage.27,28 Successful
revascularisation attenuates this type of ischaemia as well
as the generation of reactive oxygen species22 and thus
increases the nitric oxide bioavailability, which plays an
important role in arterial-wall compliance.29e31 The present
study did not assess physical activity or nitric oxide
bioavailability, but we have previously found that ﬂow-
mediated dilation, which is directly dependent on nitric
oxide, improved following successful lower-limb revascu-
larisation.22 Moreover a pharmacological intervention study
using ﬂavonoid supplementation provided evidence thatFigure 1. Ankleebrachial index in PTA group and control patients
at baseline and at 3 months follow-up. *p ¼ 0.001.
Table 4. Pressure characteristics of study population at 3-months
follow-up.
PTA (n ¼ 61) Control (n ¼ 48) p
Heart rate (bpm) 69.7 (1.3) 67.7 (1.8) 0.13
pSBP (mmHg) 141.9 (2.5) 145.7 (2.7) 0.26
pDBP (mmHg) 77.9 (1.4) 80.4 (1.4) 0.39
pMP (mmHg) 100.2 (1.7) 103 (1.7) 0.26
pPP (mmHg) 64.7 (2.2) 65.1 (2.5) 0.86
cSBP (mmHg) 130.8 (2.4) 134.8 (2.5) 0.16
cDBP (mmHg) 79 (1.4) 79.4 (2) 0.72
cPP (mmHg) 51.8 (2) 54.1 (2.4) 0.73
Data are mean and standard error of mean.bpm: Beats per minute,
BP: blood pressure, p: peripheral, c: central; S: systolic, D: diastolic,
MP: mean pressure, PP: pulse pressure.
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reﬂection and improved endothelial function.32 Therefore;
we may speculate that the observed improvement could be
due to changes in the mediators of the endothelium such as
nitric oxide. The attenuation of repeated muscle ischaemia
and improved ambulation might synergistically act towards
an improved nitric-oxide bioavailability that decreases
peripheral-tissue resistance and thereby delays pulse-wave
reﬂection, resulting in a lower AIx. In addition another
important mechanism of pulse-wave reﬂection might play
a role. The extent of arterial stiffness or obstructions and
the number and pattern of arteries and arterioles of the
distal run-off are important determinants of the timing and
amplitude of the arterial-wave reﬂection.33 Premature
arterial-wave reﬂection may occur due to arterial obstruc-
tions. Therefore, removal of obstructions in peripheral
arteries may delay wave reﬂection resulting in a decrease of
AIx.
Despite the present ﬁndings and the fact that lower-
extremity revascularisation ameliorates walking capacity, it
remains unknown whether revascularisation has a beneﬁ-
cial effect on survival. However, Jaffery et al. have recently
shown a trend towards lower 5-year mortality rates in PAD
patients following lower-limb revascularisation when
compared to PAD patients treated conservatively.34 Data
are limited so far and larger, randomised studies with clin-
ical ‘end’ points are needed to answer that question.Figure 2. Augmentation index in PTA and control patients at
baseline and at 3 months follow-up. *p ¼ 0.01.Limitation of the study
First, the present study is a controlled but non-randomised
trial on the effect of lower-limb angioplasty on markers of
arterial stiffness. Second, the ABI at baseline was signiﬁcantly
lower in the PTA group, indicating a more impaired lower-
limb perfusion in that group. Nevertheless, this limitation
does not reduce the signiﬁcance of our ﬁndings, since both
groups were followed up and only the PTA group exhibited
beneﬁcial changes of markers for arterial stiffness over this
time. Third, patients in the conservatively treated group did
not attend a supervised exercise programme, which might
have similar effects on AIx as revascularisation.This should be
further investigated, since physical activity has been shown
to decrease cardiovascular morbidity and mortality.
CONCLUSION
Our study demonstrates for the ﬁrst time that endovascular
lower-extremity revascularisation signiﬁcantly improves AIx,
a surrogate marker of arterial stiffness.CONFLICT OF INTEREST/FUNDING
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